Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Pulse Therapy for Ocular Myasthenia Gravis (ESPRETHO)
jRCTs051200137Completed
- Sponsor
- Japan Blood Products Organization
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of methylprednisolone in myasthenia gravis (MG), sponsored by Japan Blood Products Organization. Primary endpoint: Ocular MG-ADL change at 4 weeks. Started Feb 2021; status: completed.
02
Drugs
methylprednisolone
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCTs051200137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200137.